Lowering Drug Costs for Families

Summary#

This bill would change how prescription drug prices are set and how much people pay when they buy medicines. Key parts: it increases the number of drugs the federal drug price negotiation program can target from 20 to 50; lets the negotiated maximum fair prices apply to many private group and individual health plans unless those plans formally opt out; requires plans that opt out to publicly disclose that choice; adds a calculation that negotiators must consider the average price in several other countries (Australia, Canada, France, Germany, Japan, and the United Kingdom) when negotiating; and repeals a specific earlier change made by Public Law 119-21.

The bill also extends Medicare’s prescription drug inflation rebate rules so they apply to drugs sold in the commercial market (with technical changes to how units are counted and reported). Finally, it sets limits on how much people can pay out of pocket under group and individual health plans: it preserves overall out-of-pocket limits tied to existing Affordable Care Act rules for 2027 and later, adds a specific annual out-of-pocket cap for prescription drugs ($2,000 for self-only coverage in 2027, adjusted later), and creates special rules for insulin: starting in 2027, selected insulin products must be covered with no deductible and cost-sharing per 30-day supply capped at the lesser of $35 or 25% of the negotiated price.

Effective dates in the bill include plan years beginning on or after January 1, 2027 for most out-of-pocket and insulin rules, and January 1, 2028 for the requirement to consider average international market price in negotiations. Other amendments apply as described in each section.

What it means for you#

• If your group or individual health plan participates (or is treated as participating) in the drug price negotiation program, the plan must use negotiated maximum fair prices for covered selected drugs when calculating cost-sharing, so your copay, coinsurance, or other cost-sharing for those medicines cannot exceed the negotiated maximum fair price. Plans can choose not to participate but must publicly disclose that choice for each drug and period.
• There would be a new annual cap on how much you pay out of pocket for prescription drugs (the bill sets $2,000 for self-only coverage in 2027, with adjustments in later years). Family coverage caps are twice the self-only amounts.
• For selected insulin products, plans must cover at least one product per dosage form and cannot charge a deductible; cost-sharing per 30-day supply is capped at $35 or 25% of the negotiated price, whichever is lower. Payments under these insulin rules count toward your plan deductible and out-of-pocket maximum when applicable.
• If your plan opts out of the negotiation program for a drug, the plan must disclose that opt-out before the plan year starts.

Expenses#

No publicly available information on estimated federal or private-sector costs, savings, or budgetary effects is included in the bill text or metadata provided.

Proponents' View#

No publicly available information in the bill text about proponents’ stated views or supporting statements.

Opponents' View#

No publicly available information in the bill text about opponents’ stated views or objections.